Hospira is a global specialty pharmaceutical and medication delivery company that
is focused on products that improve the productivity, safety and efficacy of patient
care in the acute care setting. Hospira is a leader in the development, manufacture
and marketing of specialty injectable pharmaceuticals and medication delivery
systems that deliver drugs and intravenous (I.V.) fluids. Hospira is also a leading
provider of contract manufacturing services to pharmaceutical and biotechnology
companies for formulation development, filling and finishing of injectable pharmaceuticals.
Hospira's broad portfolio of products is used by hospitals and alternate site
providers, such as clinics, home healthcare providers and long-term care facilities,
which are together referred to as the "continuum of care."
Hospira's business has an approximately 70-year history. Prior to its spin-off
from Abbott Laboratories on April 30, 2004, Hospira's business was conducted
by Abbott, and for all periods prior to the spin-off, references in this annual
report to Hospira's historical assets, liabilities, products, businesses or
activities are generally intended to refer to the historical assets, liabilities,
products, businesses or activities of Hospira's business as it was conducted
as a part of Abbott.
Sales. Net sales in the Americas segment accounted for approximately 79% of Hospira's
Net sales. Net sales in the EMEA and APAC segments comprised approximately 13%
and 8%, respectively, of Net sales. Hospira's sales organizations include sales
professionals who sell across its major product lines, as well as product specialists
who promote its medication management products, or who market and sell Precedex™,
biosimilars, and select other products. Hospira also has extensive experience
contracting with, marketing to and servicing members of the major group purchasing
organizations ("GPOs") in the U.S. Hospira has pricing agreements for
specified products with the major GPOs in the U.S., including Amerinet, Inc.;
HealthTrust Purchasing Group LP; MedAssets Supply Chain Systems LLC; Novation,
LLC; and Premier Healthcare Alliance, LP. The scope of products included in these
agreements varies by GPO.
Customers. Hospira's primary customers in the Americas segment include hospitals,
wholesalers, integrated delivery networks ("IDN") and alternate site
facilities. In the U.S., a substantial portion of Hospira's products are sold
to GPO member hospitals, through wholesalers and distributors. Net sales through
the four largest wholesalers and distributors that supply products to many end-users
accounted for approximately 44% of global. As end-users have multiple ways to
access Hospira's products, including through more than one wholesaler or distributor,
and, in some cases, from Hospira directly, Hospira believes that it is not dependent
on any single wholesaler or distributor for distribution of its products. Hospira
has no single end-use customer that accounts for more than 10% of Net sales.
Hospira's primary customers in the EMEA and APAC segments are hospitals and
wholesalers that Hospira serves through its own sales force and its distributors.
Primary customers in EMEA also include private oncologists and compounding pharmacists.
The majority of Hospira's business in the EMEA and APAC segments is conducted
through contracting with individual hospitals or through regional or national
tenders whereby Hospira submits bids to sell its products.
Distribution. In the U.S., Hospira's products are primarily distributed through
a network of company-operated distribution facilities and third-party logistics
providers. The primary company-operated distribution facilities are identified
in "Item 2. Properties" of this report. For the remainder of the Americas
segment outside the U.S. and for the EMEA and APAC segments, Hospira primarily
utilizes third-party logistics providers and external distributors in markets
where Hospira does not have a direct commercial establishment.
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
COMPANY NAME
MARKET CAP
REVENUES
INCOME
EMPLOYEES
0.00
6,921.20
415.10
-
SUBTOTAL
0.00
0.00
0.00
-
Sources:
Hospira Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Hospira Inc’s corporate clients.
For your research, we’ve provided 9 tables on Hospira Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
